{
    "clinical_study": {
        "@rank": "31772", 
        "arm_group": [
            {
                "arm_group_label": "Combination A", 
                "arm_group_type": "Experimental", 
                "description": "QuickShot\u2122 and testosterone enanthate- combination A"
            }, 
            {
                "arm_group_label": "Combination B", 
                "arm_group_type": "Experimental", 
                "description": "QuickShot\u2122 and testosterone enanthate- combination B"
            }, 
            {
                "arm_group_label": "Delatestryl/needle/syringe", 
                "arm_group_type": "Active Comparator", 
                "description": "Commercially obtained Testosterone enanthate 200 mg dose standard of care arm for reference"
            }
        ], 
        "brief_summary": {
            "textblock": "Relative bioavailability and safety comparison of 3 formulations of testosterone enanthate."
        }, 
        "brief_title": "Pharmacokinetic Study of Testosterone Enanthate", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hypogonadism", 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "detailed_description": {
            "textblock": "Standard pharmacokinetic analyses of blood concentration data for serum testosterone,\n      dihydrotestosterone and estradiol comparing, Cmax, area under the concentration time curve,\n      and average blood concentration to facilitate the comparison of the relative bioavailability\n      of the treatment and control arms.  Safety comparisons will be based upon the occurrence,\n      severity and rate of treatment emergent adverse events and measurement of standard safety\n      laboratory parameters, as well as assessment of the frequency and severity of any\n      derangements of laboratory parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult males aged 18 to 75 with a documented diagnosis of hypogonadism\n\n        Exclusion Criteria:\n\n          -  Normal testosterone levels\n\n          -  Subjects with any clinically significant medical condition which, in the opinion of\n             the Investigator, would make the subject an unsuitable candidate for enrollment in\n             the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887418", 
            "org_study_id": "QST 13002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combination B", 
                "description": "QuickShot\u2122 for the delivery of testosterone", 
                "intervention_name": "QuickShot\u2122 and testosterone enanthate- combination B", 
                "intervention_type": "Drug", 
                "other_name": "Testosterone, testosterone enanthate"
            }, 
            {
                "arm_group_label": "Combination A", 
                "description": "QuickShot\u2122 for the delivery of testosterone", 
                "intervention_name": "QuickShot\u2122 and testosterone enanthate- combination A", 
                "intervention_type": "Drug", 
                "other_name": "testosterone, testosterone enanthate"
            }, 
            {
                "arm_group_label": "Delatestryl/needle/syringe", 
                "description": "Standard of care", 
                "intervention_name": "Delatestryl/needle/syringe", 
                "intervention_type": "Drug", 
                "other_name": "testosterone, testosterone enanthate"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hypogonadism", 
            "Testosterone enanthate"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brookline", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02445"
                }, 
                "name": "Mens Health Boston"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "3 Arm, Open-label, Randomized, Multidose Parallel Group Study of Pharmacokinetics, Safety, and Tolerability of Two Dose Levels of a Formulation of Testosterone Enanthate in a Device or Needle and Syringe in Hypogonadal Adult Male", 
        "overall_official": {
            "affiliation": "Prestige Clinical Research", 
            "last_name": "Gary Bedel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "7 or 14 days of blood sampling following dosing to determine the average concentration, maximum observed plasma concentration (Cmax), area under the curve from time zero to last quantifiable concentration [AUC (0-t)]", 
            "measure": "Relative bioavailability of testosterone enanthate formulations", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887418"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Collection of overall treatment emergent adverse events, and determination of frequency of TEAE for each system organ class, in order to determine whether a pattern(s) is present.\nCollections of routine labs and prostate specific antigen to determine whether there are laboratory abnormalities associated with study drug admininstration.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "source": "Antares Pharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Antares Pharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}